This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Non-Hodgkin lymphoma
  • /
  • Diffuse large B-cell lymphoma (DLBCL): ESMO Clinic...

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Read time: 1 mins
Published:25th Aug 2015
Author: Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al.
Availability: Free full text
Ref.:Ann Oncol. 2015 Sep;26 Suppl 5:v116-25.
DOI: 10.1093/annonc/mdv304.

Diffuse large B-cell lymphoma (DLBCL) constitutes 30%–58% of non-Hodgkin's lymphoma series. The crude incidence in Europe is 3.8/100 000/year. The incidence increases with age and varies considerably across Europe. A family history of lymphoma, autoimmune disease, human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) seropositivity, a high body mass as a young adult and some occupational exposures have been identified as risk factors of DLBCL. In recent years, there have been important survival improvements for DLBCL in all European regions.


Read abstract on library site

Access full article